Q-omics provides the consensus-scored QTRT1 profile across patient tissues and cancer cell-line models. QTRT1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, QTRT1 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, QTRT1 protein abundance shows 21,219 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight CESC, KIRC, and GBM as cancer lineages where QTRT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for QTRT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes QTRT1 survival associations across molecular data types. QTRT1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible QTRT1 RNA expression–survival associations across cancer types. High QTRT1 expression shows unfavorable associations in ACC, COAD, LGG and KIRC, but favorable associations in CESC and BLCA. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for QTRT1 RNA expression.
This table summarizes QTRT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for QTRT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. QTRT1 shows lower tumor expression in THCA and higher tumor expression in KIRC, COAD, STAD, LIHC and HNSC. The KIRC box plot shows higher QTRT1 RNA expression in tumor versus normal tissue (log2 FC = +0.877, t-test p < 0.001).
This table shows molecular features associated with QTRT1 in patient tissues and cancer cell lines. In patient samples, QTRT1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, QTRT1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and BONE.
